98 related articles for article (PubMed ID: 11544910)
1. [Vinorelbine in patients with malignant pleural mesothelioma--a phase II study].
Ost E; Illiger HJ
Strahlenther Onkol; 2001 Aug; 177(8):440-1. PubMed ID: 11544910
[No Abstract] [Full Text] [Related]
2. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma.
Stebbing J; Powles T; McPherson K; Shamash J; Wells P; Sheaff MT; Slater S; Rudd RM; Fennell D; Steele JP
Lung Cancer; 2009 Jan; 63(1):94-7. PubMed ID: 18486273
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma.
Lu C; Perez-Soler R; Piperdi B; Walsh GL; Swisher SG; Smythe WR; Shin HJ; Ro JY; Feng L; Truong M; Yalamanchili A; Lopez-Berestein G; Hong WK; Khokhar AR; Shin DM
J Clin Oncol; 2005 May; 23(15):3495-501. PubMed ID: 15908659
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of vinorelbine in patients with malignant pleural mesothelioma.
Steele JP; Shamash J; Evans MT; Gower NH; Tischkowitz MD; Rudd RM
J Clin Oncol; 2000 Dec; 18(23):3912-7. PubMed ID: 11099320
[TBL] [Abstract][Full Text] [Related]
5. Vindesine in the treatment of malignant mesothelioma: a phase II study.
Kelsen D; Gralla R; Cheng E; Martini N
Cancer Treat Rep; 1983 Sep; 67(9):821-2. PubMed ID: 6883358
[TBL] [Abstract][Full Text] [Related]
6. Adapting the Lung Cancer Symptom Scale (LCSS) to mesothelioma: using the LCSS-Meso conceptual model for validation.
Hollen PJ; Gralla RJ; Liepa AM; Symanowski JT; Rusthoven JJ
Cancer; 2004 Aug; 101(3):587-95. PubMed ID: 15274072
[TBL] [Abstract][Full Text] [Related]
7. Pemetrexed and cisplatin for malignant pleural mesothelioma: a new standard of care?
Rusch VW
J Clin Oncol; 2003 Jul; 21(14):2629-30. PubMed ID: 12860935
[No Abstract] [Full Text] [Related]
8. Phase II study of vinflunine in malignant pleural mesothelioma.
Talbot DC; Margery J; Dabouis G; Dark G; Taylor H; Boussemart H; Cadic V; Pinel MC; Rivière A; Ollivier L; Ruffié P
J Clin Oncol; 2007 Oct; 25(30):4751-6. PubMed ID: 17947722
[TBL] [Abstract][Full Text] [Related]
9. Phase II trials in mesothelioma: an increasing challenge.
Nowak AK
Lung Cancer; 2005 Oct; 50(1):87-90. PubMed ID: 16026892
[No Abstract] [Full Text] [Related]
10. Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I/II study in Japanese patients.
Nakagawa K; Yamazaki K; Kunitoh H; Hida T; Gemba K; Shinkai T; Ichinose Y; Adachi S; Nambu Y; Saijo N; Fukuoka M
Jpn J Clin Oncol; 2008 May; 38(5):339-46. PubMed ID: 18434338
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of vindesine in malignant pleural mesothelioma.
Boutin C; Irisson M; Guérin JC; Roegel E; Paramelle B; Brambilla C; Jeannin L; Dabouis G; Le Caer H; Viallat JR
Cancer Treat Rep; 1987 Feb; 71(2):205-6. PubMed ID: 3802116
[No Abstract] [Full Text] [Related]
12. MVP and vinorelbine for malignant pleural mesothelioma.
Mordant P; Loriot Y; Soria JC; Deutsch E
Lancet; 2008 Aug; 372(9639):629; author reply 629-30. PubMed ID: 18722865
[No Abstract] [Full Text] [Related]
13. Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: feasibility and responsiveness to clinical changes.
Ribi K; Bernhard J; Schuller JC; Weder W; Bodis S; Jörger M; Betticher D; Schmid RA; Stupp R; Ris HB; Stahel RA;
Lung Cancer; 2008 Sep; 61(3):398-404. PubMed ID: 18433927
[TBL] [Abstract][Full Text] [Related]
14. [Chemotherapy of malignant pleural mesothelioma: have we made any progress?].
Reck M; Heigener DF; Gatzemeier U
Zentralbl Chir; 2008 Jun; 133(3):238-42. PubMed ID: 18563688
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma.
Lucchi M; Chella A; Melfi F; Dini P; Ambrogi M; Fino L; Fontanini G; Mussi A
Eur J Cardiothorac Surg; 2007 Mar; 31(3):529-33; discussion 533-4. PubMed ID: 17188885
[TBL] [Abstract][Full Text] [Related]
16. Optimising survival in malignant mesothelioma.
Baas P
Lung Cancer; 2007 Aug; 57 Suppl 2():S24-9. PubMed ID: 17686442
[TBL] [Abstract][Full Text] [Related]
17. Advances in the systemic therapy of malignant pleural mesothelioma.
Fennell DA; Gaudino G; O'Byrne KJ; Mutti L; van Meerbeeck J
Nat Clin Pract Oncol; 2008 Mar; 5(3):136-47. PubMed ID: 18227828
[TBL] [Abstract][Full Text] [Related]
18. Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients.
Porta C; Zimatore M; Bonomi L; Imarisio I; Paglino C; Sartore-Bianchi A; Mutti L
Lung Cancer; 2005 Jun; 48(3):429-34. PubMed ID: 15893013
[TBL] [Abstract][Full Text] [Related]
19. Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.
Guadagni S; Clementi M; Valenti M; Fiorentini G; Cantore M; Kanavos E; Amicucci G
In Vivo; 2006; 20(6A):715-8. PubMed ID: 17203752
[TBL] [Abstract][Full Text] [Related]
20. Effective chemotherapy based on a chemosensitivity test for malignant pleural mesothelioma.
Maniwa Y; Yoshimura M; Takata M; Nishimura Y; Ohno Y
Ann Thorac Cardiovasc Surg; 2008 Oct; 14(5):319-21. PubMed ID: 18989249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
